Similarly, PD-L1 inhibitors, such as durvolumab or atezolizumab, have reported low efficacy in patients with GBM, with only minimal survival improvement for a subgroup of GBM patients with mismatch repair deficiency [187,188]. The gene discussed is CD274; the disease is glioblastoma.